Joost J Neijssen

USPTO Granted Patents = 15 (Patent Applications = 18)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 19)

Average Co-Inventor Count = 8.3

ph-index = 7

Forward Citations = 242(Granted Patents)

Location History:

Werkhoven, NL (2015 - 2024)
Utrecht, NL (2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11932693 - Monoclonal antibodies directed against programmed death-1 protein and their use in medicine (2024-03-19),

2. 11866514 - Heterodimeric antibody Fc-containing proteins and methods for production thereof (2024-01-09),

3. 11613575 - Humanized or chimeric CD3 antibodies (2023-03-28),

4. 11578141 - Bispecific antibodies against HER2 and CD3 (2023-02-14),

5. 11512140 - Monoclonal antibodies against c-Met (2022-11-29),

6. 11492371 - Production of heterodimeric proteins (2022-11-08),

7. 11485796 - Inert format (2022-11-01),

8. 10597464 - Heterodimeric antibody Fc-containing proteins and methods for production thereof (2020-03-24),

9. 10590206 - Inert format (2020-03-17),

10. 10465006 - Humanized or chimeric CD3 antibodies (2019-11-05),

11. 10407501 - Humanized or chimeric CD3 antibodies (2019-09-10),

12. 10344050 - Production of heterodimeric proteins (2019-07-09),

13. 9657107 - Monoclonal antibodies against c-Met (2017-05-23),

14. 9150663 - Heterodimeric antibody Fc-containing proteins and methods for production thereof (2015-10-06),

15. 9068011 - Monoclonal antibodies against c-Met (2015-06-30),

Title: Joost J Neijssen: Innovating Healthcare Solutions through Patents

Introduction: Joost J Neijssen, a renowned inventor based in Werkhoven, NL, has made significant contributions to the field of healthcare with his 14 patents. His latest inventions include groundbreaking advancements in antibody technology for the treatment of various diseases.

Latest Patents:

1. Heterodimeric antibody Fc-containing proteins: Joost Neijssen's innovative work involves the development of novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies. These proteins offer new possibilities for targeted therapy and improved treatment outcomes.

2. Humanized or chimeric CD3 antibodies: In another revolutionary patent, Joost Neijssen has introduced humanized or chimeric antibodies that bind CD3. These antibodies have the potential to enhance the body's immune response and combat diseases more effectively.

Career Highlights: Joost Neijssen is a key member of the renowned company Genmab A+s, where he continues to drive innovation in the healthcare industry. His expertise in biotechnology and antibody research has paved the way for groundbreaking solutions that benefit patients worldwide.

Collaborations: Joost Neijssen collaborates closely with accomplished professionals in the field, including Aran Frank Labrijn and Janine Schuurman. Together, they form a dynamic team dedicated to pushing the boundaries of scientific discovery and bringing new therapies to market.

Conclusion: Joost J Neijssen's commitment to innovation and his passion for transforming healthcare through patents demonstrate his profound impact on the industry. His contributions have the potential to improve the lives of countless individuals and pave the way for a brighter, healthier future.

This text is generated by artificial intelligence and may not be accurate.